Source:http://linkedlifedata.com/resource/umls/id/C1134718
PDQ: A genetic engineered herpes simplex virus (HSV-1) mutant strain, with antineoplastic property. G207 is an attenuated, replication-competent, engineered to selectively replicate within cancer cells. This oncolytic HSV mutant virus has defects in genes encoding for both ribonucleotide reductase and the neurovirulence factor, ICP34.5 (gamma34.5), and is thus neuroattenuated. G207 has potent anticancer vaccination effects due to its cytotoxicity to cancer cells. Furthermore, it can be used as a gene transfer vector without compromising safety. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38634&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38634&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2676" NCI Thesaurus),NCI: A neuroattenuated, replication-competent, recombinant herpes simplex virus-1 (HSV-1) with potential oncolytic activity. Up